文献速递胸部肿瘤

呼出气电子鼻分析用于肺癌检测:一项多中心前瞻性外部验证研究

Lung cancer detection by electronic nose analysis of exhaled breath: a multicentre prospective external validation study.
PubMed 文献 · Ann Oncol · 2025-03-31

该多中心前瞻性外部验证研究纳入364例临床和/或影像学怀疑肺癌的成人,采用SpiroNose®电子鼻分析呼出气。原模型在COPD患者中ROC-AUC为0.92,在全部参与者中为0.80;新模型验证队列ROC-AUC为0.83、敏感度94%、特异度63%。结论认为电子鼻分析可在胸科肿瘤门诊实现准确肺癌检测。

要点

  • 原电子鼻模型在COPD患者中检测肺癌ROC-AUC为0.92(95%CI 0.85-0.99),全部参与者为0.80(95%CI 0.75-0.85)。
  • 原模型在95%敏感度下,COPD患者与全部参与者的特异度分别为72%和51%,PPV分别为95%和74%,NPV分别为72%和88%。
  • 新电子鼻模型验证队列ROC-AUC为0.83(95%CI 0.75-0.91),敏感度94%、特异度63%、PPV 79%、NPV 89%。

核心结论

  • 该多中心前瞻性外部验证研究证实,电子鼻分析呼出气可在胸科肿瘤门诊准确检测肺癌,且不受肿瘤特征、疾病分期、诊断中心和临床特征影响。

研究设计与样本

  • 多中心前瞻性外部验证研究,纳入荷兰两个中心胸科肿瘤门诊中临床和/或影像学怀疑肺癌的成人,2019年3月至2023年11月共纳入364例参与者。
  • 使用云端连接的电子鼻(SpiroNose®)采集呼出气图谱。
  • 评估原电子鼻模型和针对目标人群定制的新电子鼻模型的诊断性能,新模型使用训练队列和验证队列。

主要发现

  • 原电子鼻模型在COPD患者中检测肺癌的ROC-AUC为0.92(95%CI 0.85-0.99),在全部参与者中为0.80(95%CI 0.75-0.85)。
  • 原模型在95%敏感度下,COPD患者与全部参与者的特异度分别为72%和51%,PPV分别为95%和74%,NPV分别为72%和88%。
  • 新电子鼻模型在验证队列全部参与者中识别肺癌的ROC-AUC为0.83(95%CI 0.75-0.91),敏感度94%、特异度63%、PPV 79%、NPV 89%。
  • 准确检测在肿瘤特征、疾病分期、诊断中心和临床特征方面保持一致。

关键数值与推荐

  • 原电子鼻模型在COPD患者中检测肺癌ROC-AUC为0.92(95%CI 0.85-0.99)。
  • 原电子鼻模型在全部参与者中检测肺癌ROC-AUC为0.80(95%CI 0.75-0.85)。
  • 原模型在95%敏感度下,COPD患者特异度72%、PPV 95%、NPV 72%;全部参与者特异度51%、PPV 74%、NPV 88%。
  • 新电子鼻模型验证队列ROC-AUC为0.83(95%CI 0.75-0.91),敏感度94%、特异度63%、PPV 79%、NPV 89%。

临床怎么用

  • 原文结论认为电子鼻分析呼出气可在胸科肿瘤门诊实现准确肺癌检测,不受肿瘤特征、疾病分期、诊断中心和临床特征影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Electronic nose (eNose) analysis of exhaled breath shows potential for accurate and timely lung cancer diagnosis, yet prospective external validation studies are lacking. Our study primarily aimed to prospectively and externally validate a published eNose model for lung cancer detection in chronic obstructive pulmonary disease (COPD) patients and assess its diagnostic performance alongside a new eNose model, specifically tailored to the target population, in a more general outpatient population. PATIENTS AND METHODS: This multicentre prospective external validation study included adults with clinical and/or radiological suspicion of lung cancer who were recruited from thoracic oncology outpatient clinics of two sites in the Netherlands. Breath profiles were collected using a cloud-connected eNose (SpiroNose®). The diagnostic performance of the original and new eNose models was assessed in various population subsets based on receiver operating characteristic-area under the curve (ROC-AUC), specificity, positive predictive value (PPV), and negative predictive value (NPV), targeting 95% sensitivity. For the new eNose model, a training cohort and a validation cohort were used. RESULTS: Between March 2019 and November 2023, 364 participants were included. The original eNose model detected lung cancer with an ROC-AUC of 0.92 [95% confidence interval (CI) 0.85-0.99] in COPD patients (n = 98/116; 84%) and 0.80 (95% CI 0.75-0.85) in all participants (n = 216/364; 59%). At 95% sensitivity, the specificity, PPV, and NPV, were 72% and 51%, 95% and 74%, and 72% and 88%, respectively. In the validation cohort, the new eNose model identified lung cancer across all participants (n = 72/121; 60%) with an ROC-AUC of 0.83 (95% CI 0.75-0.91), sensitivity of 94%, specificity of 63%, PPV of 79%, and NPV of 89%. Notably, accurate detection was consistent across tumour characteristics, disease stage, diagnostic centres, and clinical characteristics. CONCLUSION: This multicentre prospective external validation study confirms that eNose analysis of exhaled breath enables accurate lung cancer detection at thoracic oncology outpatient clinics, irrespective of tumour characteristics, disease stage, diagnostic centre, and clinical characteristics.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Buma AIG, Muntinghe-Wagenaar MB, van der Noort V, et al. Lung cancer detection by electronic nose analysis of exhaled breath: a multicentre prospective external validation study. Ann Oncol. 2025. PMID: 40174676. doi:10.1016/j.annonc.2025.03.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。